A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis.

MLA

Pettit K., et al. A Phase 2a Study of the LSD1 Inhibitor Img-7289 (Bomedemstat) for the Treatment of Myelofibrosis. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305108053&authtype=sso&custid=ns315887. Accessed 28 Nov. 2024.

APA

Pettit K., Gerds A.T., Yacoub A., Watts J.M., Tartaczuch M., Bradley T.J., Shortt J., Stevenson W.S., Curtin N.J., Rossetti J.M., Burbury K., Natsoulis G., Jones A., Talpaz M., Peppe J., Ross D.M., & Rienhoff H.Y. (n.d.). A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis.

Chicago

Pettit K., Gerds A.T., Yacoub A., Watts J.M., Tartaczuch M., Bradley T.J., Shortt J., et al. 2024. “A Phase 2a Study of the LSD1 Inhibitor Img-7289 (Bomedemstat) for the Treatment of Myelofibrosis.” Accessed November 28. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305108053&authtype=sso&custid=ns315887.